( MENAFN - GlobeNewsWire - Nasdaq) The Global Cardiovascular Clinical Trials market Size was Valued at USD 5.36 Billion in 2023 and the Worldwide Cardiovascular Clinical Trials Market Size is Expected to Reach USD 9.76 Billion by 2033, according to a research report published by Spherical Insights & Consulting covered: ICON plc, Eli Lilly and Company, Syneos Health, Worldwide Clinical Trials, Veeda Clinical Research, IQVIA Inc, SGS SA, PPD Inc, Caidya, Vial, Medpace, Inc.
, Thermo Fisher Scientific, Merck & Co, Pfizer, Others New York, United States , June 11, 2024 (GLOBE NEWSWIRE) -- The Global Cardiovascular Clinical Trials Market Size is to Grow from USD 5.36 Billion in 2023 to USD 9.76 Billion by 2033, at a CAGR of 6.
18% during the projected period. Get a Sample PDF Brochure: Clinical trials for cardiovascular health are systematic investigations conducted on human subjects to assess the overall effect, safety, and efficacy of new drugs, medical devices, or treatments related to cardiovascular health. Strict scientific and ethical requirements are adhered to during these trials in order to ensure the validity of the findings.
Through investigating cardiovascular illnesses, including heart failure, coronary artery disease, and stroke, prevention, diagnostic, and treatment strategies, these trials aim to advance medical knowledge and improve patient outcomes. There are four stages of conducting clinical trials: phase I, phase II, phase III, and phase IV. The growing prevalen.